Research Topics
| Ludmila KryzhanovskayaSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapineLudmila A Kryzhanovskaya
Lilly Research Laboratories, Indianapolis, Indiana 46285 6156, USA
J Child Adolesc Psychopharmacol 22:157-65. 2012..The purpose of these analyses was to compare the weight and other metabolic changes between adolescents and adults during long-term (at least 24 weeks) olanzapine treatment...
A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementiaLudmila A Kryzhanovskaya
Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285 6156, USA
J Clin Psychiatry 67:933-45. 2006..Although antipsychotics may be efficacious in this population, elderly patients with dementia may be particularly vulnerable to adverse events. This article reviews the safety of olanzapine in elderly patients with dementia...- The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trialsLudmila A Kryzhanovskaya
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285 6156, USA
J Clin Psychiatry 70:247-58. 2009..To describe the safety of olanzapine treatment in adolescents (aged 13-17 years) with schizophrenia or bipolar I disorder, and to compare these data with those of olanzapine-treated adults... - Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trialLudmila Kryzhanovskaya
Eli Lilly and Company
J Am Acad Child Adolesc Psychiatry 48:60-70. 2009..To assess olanzapine's efficacy and tolerability in adolescents with schizophrenia... - Olanzapine versus placebo in the treatment of adolescents with bipolar maniaMauricio Tohen
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
Am J Psychiatry 164:1547-56. 2007..The purpose of this study was to evaluate the efficacy and safety of olanzapine for the treatment of acute manic or mixed episodes associated with bipolar disorder in adolescents... - A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophreniaBruce J Kinon
Eli Lilly and Company, Indianapolis, IN, USA
J Clin Psychopharmacol 31:349-55. 2011..Additional efficacy, safety, and tolerability testing are needed... - Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind studyMauricio Tohen
Lilly Research Laboratories, 450 South Madison Ave, Indianapolis, IN 46225, USA
J Clin Psychiatry 69:1776-89. 2008..To evaluate the efficacy and safety of olanzapine, divalproex, and placebo in a randomized, double-blind trial in mild to moderate mania (DSM-IV-TR criteria)... - Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychoticsThomas A Hardy
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 26:405-8. 2006..Although interpretation of this study is limited by the cross-sectional study design, it provides additional insight concerning the relationship between antipsychotic use and plasma lipid parameters in this population... - Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studiesMosun Ayan-Oshodi
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 32:408-11. 2012..There were no clinically significant changes in electroencephalograms in subjects receiving LY2140023 (n = 26). LY2140023 was generally well tolerated in healthy subjects... - Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North AfricaMartin Dossenbach
Eli Lilly Austria Medical Department, Eli Lilly Regional GmbH, Vienna, Austria
J Clin Psychopharmacol 27:329-37. 2007..09 +/- 1.11; chlorpromazine, 0.72 +/- 2.04; P = 0.042). This analysis suggests that, compared with chlorpromazine, olanzapine may be more efficacious and have a more favorable tolerability profile in treating patients with schizophrenia... - Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trialsIlya Lipkovich
Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA
Psychopharmacol Bull 42:23-39. 2009..These results confirm that cut-offs for weight gain during the first 4 weeks of treatment may be useful in evaluating SWG risk for an individual patient... - Diabetes mellitus and antipsychotic treatment in the United KingdomChristopher Carlson
Eli Lilly and Company, Indianapolis, IN, USA
Eur Neuropsychopharmacol 16:366-75. 2006..CONCLUSION: Consistent with other epidemiology studies, this study supports an increased risk of developing diabetes during treatment with antipsychotics... - Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodesMauricio Tohen
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Br J Psychiatry 192:135-43. 2008..Combinations of olanzapine and carbamazepine are often used in clinical practice in the management of mania... - Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trialsPatrizia A Cavazzoni
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Clin Psychiatry 67:107-13. 2006..The present analysis retrospectively examined olanzapine clinical trial data for incidence of treatment-emergent EPS in patients with either schizophrenia or bipolar disorder...